Deciphera Pharma Stock Price, News & Analysis

Deciphera Pharmaceuticals (NASDAQ: DCPH) will host a virtual investor event on September 17, 2021, from 10:00 AM to 12:30 PM ET, to discuss clinical data for rebastinib and vimseltinib ahead of the ESMO Congress 2021. Key speakers include Dr. Robert L. Coleman and Dr. William D. Tap. The event will be webcast live and available for replay on Deciphera's website. Deciphera is committed to developing innovative cancer treatments, highlighted by its FDA-approved drug QINLOCK, used for fourth-line gastrointestinal stromal tumors.

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021, at 2:45 PM ET. The conference will be held virtually, and a live webcast will be available on the company's website. Deciphera focuses on developing new medicines for cancer treatment, including QINLOCK®, its FDA-approved drug for fourth-line gastrointestinal stromal tumor (GIST), also approved in Australia, Canada, China, and Hong Kong.

Deciphera Pharmaceuticals (NASDAQ:DCPH) reported Q2 2021 financial results, achieving $23.6 million in total revenue, including $22.0 million from QINLOCK sales. R&D expenses rose to $60.0 million due to ongoing studies. Despite these efforts, the company posted a net loss of $70.4 million, slightly higher than the previous year. QINLOCK continues its expansion with approvals in China and upcoming EMA decisions. Key milestones include reporting Phase 3 study data and initiating new trials in late 2021.

Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its second quarter 2021 financial results on August 3, 2021. The management team will host a conference call at 4:30 PM ET on the same day to discuss the results and provide corporate updates. Investors can access the call by dialing the provided numbers or via the webcast on the Company’s website. Deciphera focuses on developing innovative treatments for cancer, including its FDA-approved QINLOCK® for gastrointestinal stromal tumors.

Deciphera Pharmaceuticals (NASDAQ: DCPH) has initiated dose administration for the first patient in a Phase 1 clinical trial of DCC-3116, an investigational ULK kinase inhibitor targeting advanced tumors with RAS or RAF mutations. This study, designed as a multicenter, open-label trial, will evaluate DCC-3116 as a single agent and in combination with trametinib, a FDA-approved MEK inhibitor. The focus is on various cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. DCC-3116 aims to address significant unmet medical needs in oncology through its unique mechanism of inhibiting autophagy.

Deciphera Pharmaceuticals (NASDAQ: DCPH) presented new data at the 2021 ASCO Annual Meeting regarding QINLOCK for advanced gastrointestinal stromal tumor (GIST) and rebastinib for endometrial cancer. The INVICTUS Phase 3 study showed that patients escalating QINLOCK dose to 150 mg BID achieved a median overall survival of 18.4 months. In the rebastinib study, an objective response rate of 33% was noted in endometrial cancer patients. Deciphera aims to finalize development plans for rebastinib and share further results in late 2021.

Deciphera Pharmaceuticals (NASDAQ: DCPH) has announced that Steve Hoerter, President and CEO, will participate in fireside chats at two investor conferences. The Jefferies Virtual Healthcare Conference is set for June 3, 2021, at 1:30 PM ET, and the JMP Securities Life Sciences Conference will follow on June 16, 2021, at 4:00 PM ET. Live webcasts of these events will be accessible on the Company’s Investors page, with replays available for 90 days.

Deciphera specializes in developing new medicines for cancer, utilizing its proprietary kinase inhibitor platform.

Deciphera Pharmaceuticals (NASDAQ:DCPH) reported its Q1 2021 financial results, highlighting a net product revenue of $20.0 million from QINLOCK, including $19.3 million from U.S. sales. The company will initiate a Phase 1b/2 study combining QINLOCK with binimetinib and expects top-line results from the INTRIGUE Phase 3 study in the fourth quarter. R&D expenses increased to $55.7 million. Despite a net loss of $61.3 million, Deciphera's cash position remains strong at $502.2 million, sufficient to fund operations into the first half of 2023.

Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its first quarter 2021 financial results on May 4, 2021. A conference call to discuss these results and provide corporate updates will follow at 4:30 PM ET on the same day. Interested parties can join the call via toll-free or international numbers and access the live webcast on the Company’s investor relations page. Deciphera specializes in innovative cancer treatments, including QINLOCK®, its FDA-approved therapy for fourth-line gastrointestinal stromal tumors.